Navigation Links
eFoodSafety.com Selects Arcand & Madison as Public Relations Counsel and The Ruth Group as Investor Relations Counsel
Date:1/26/2009

SCOTTSDALE, Ariz., Jan. 26 /PRNewswire-FirstCall/ -- eFoodSafety.com, Inc. (OTC Bulletin Board: EFSF.OB), an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products, today announced signing one year contracts with Arcand & Madison Public Relations and The Ruth Group (TRG).

Recently, eFoodSafety.com entered into a definitive agreement to merge with Freedom2 Holdings, Inc. The merger is on track to close on or before February 28, 2009.

"We are partnering with Arcand & Madison and TRG to ensure strong, ongoing communications," stated Martin Schmieg, current president and CEO of Freedom2, Inc. and future Chairman and CEO of eFoodSafety.com, Inc. "We expect that for the growing market of individuals looking for safer, more trustworthy health care alternatives, information from eFoodSafety will be welcome news."

Ms. Pat Arcand, Partner, Arcand & Madison, said, "Working with eFoodSafety is an opportunity to educate the public about the benefits of a new class of scientifically developed and tested consumer health care products."

Ms. Carol Ruth, President of The Ruth Group, said "We welcome the opportunity to demonstrate that eFoodSafety.com is a compelling investment opportunity in the growing healthcare market."

Both agencies have been retained for one year for a total cost of $120,000.

About eFoodSafety.com, Inc.

eFoodSafety is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercialized healthcare products that address the health needs of consumers worldwide.

About Freedom2 Holdings, Inc.

Freedom2, Inc. is a diversified skin products technology company serving the fast-growing body art
'/>"/>

SOURCE eFoodSafety.com, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Lance Armstrong Foundation Selects Ogilvy Public Relations Worldwide to Support the LIVESTRONG Global Cancer Campaign
2. Fairview Baptist Home Selects PatientPlacement.com to Automate Referrals and Increase Patient and Resident Admissions
3. Childrens Hospital Central California Selects Turner to Manage Addition and Renovation Project
4. Yalobusha General Hospital Selects HMS to Provide Information Technology Infrastructure
5. Tomball Regional Medical Center Selects Clinical Xpert(TM) from Thomson Reuters to Lead Quality Improvement Initiatives
6. Tennessee Hospital Association Selects PivotHealth To Provide Hospital-Physician Alignment Services
7. Schering-Plough Selects Benefit Advocates for Health Advocacy
8. RPGSi Selects M2SYS Fingerprint Biometrics Software for Revolutionary Patient Identification System
9. Womans Hospital Selects rL Solutions for Improved Adverse Event and Patient Safety Reporting
10. Michigan CardioVascular Institute Selects Sage Intergy EHR to Streamline Clinical, Workflow and Reporting Efficiencies
11. Business First Selects DRE Medical Equipment as a Company of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Winter Spare the Air Alert in Effect for Thursday November 26 2009 62162 1Winter Spare the Air Alert in Effect for Thursday November 26 2009 62162 2Heska Announces Supply Agreement With Roche Diagnostics 6549 1Heska Announces Supply Agreement With Roche Diagnostics 6549 2Heska Announces Supply Agreement With Roche Diagnostics 6549 3Engineers doctors at UCLA develop novel material that could help fight arterial disease 62158 1Engineers doctors at UCLA develop novel material that could help fight arterial disease 62158 2Engineers doctors at UCLA develop novel material that could help fight arterial disease 62158 3Engineers doctors at UCLA develop novel material that could help fight arterial disease 62158 4